Close Menu

If there was a single word that defined the proteomics world in 2003, it would have to be ‘biomarker.’ Nearly all of the 11 leading researchers interviewed for this issue named biomarkers, and in particular their application to pattern-based clinical diagnostics and toxicology, as one of the most memorable developments of 2003 — and pointed to 2004 as a defining year for determining whether the trend will continue to boom, or whether it will bust.

The Explosion

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Nature News writes that scientists are trying to figure out how to name the new strains of SARS-CoV-2 that are emerging.

The New York Times reports that researchers are studying identical twins who had COVID-19 to understand the influence of genetics on disease severity.

In PNAS this week: epistasis affecting cystic fibrosis, Tiger rattlesnake genome gives venom insight, and more.

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.